PAGR1 Knockout cell line (ACHN)

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

PAGR1 (PAXIP1 associated glutamate rich protein 1) encodes a nuclear protein that participates in the MLL3/4 complex and interacts with estrogen receptors. It positively regulates G1/S cell-cycle transition, intracellular estrogen receptor signaling, and RNA polymerase II-dependent transcription. PAGR1 therefore contributes to transcriptional regulation and cell-cycle control, particularly in pathways responsive to estrogen receptor signaling.

Initiated in November 1979, ACHN is a well-established human cell line derived from the malignant pleural effusion of a 22-year-old Caucasian male with widely metastatic renal adenocarcinoma. The cells were originally seeded directly into culture flasks in Eagle’s MEM supplemented with 10% FBS, and maintained through passages for 150 days before being inoculated subcutaneously into nude mice, where they formed palpable, locally invasive tumors within four weeks. Notably, both the parental ACHN cells and those recovered from the nude mouse tumors are distinctly growth-inhibited by human interferons, making ACHN a premier in vitro and in vivo model platform for investigating renal oncology progression, cytokine responses, and preclinical drug evaluation.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.